Healthcare & Life Sciences Blog -

New White House Executive Order to Establish “Most-Favored-Nation” Drug Pricing

by Michelle Carr, Kerry B. Contini, Maria Eberle, Jane E. Hobson, Oren Livne, Jennifer Ancona Semko, Randall B. Sunberg, Xin Tao, Olivia Tyrrell, Alan F. Zoccolillo, Jr. and Lois Sheng Liu

Medical Devices

US Tariffs and the Life Science industry – an update

by Chandri Navarro, Jennifer F. Revis, Sophie Delhoulle and Magda Tovar

Digital Health

The Healthcare Agenda of Germany’s New CDU/SPD Coalition Government – A Point-by-Point Analysis of Key Policies and Their Potential Implications for Pharma and Med-Tech Companies

by Dr. Frank Pflueger and Johannes Blaensdorf

Medical Devices

Switzerland’s Therapeutic Products Act Revision: Industry Stakeholders Show Positive Support

by Dr. iur. Julia Schieber, Nadine Charrière and Selina Bähler

Medical Devices

European Commission Proposes Act to Secure Critical Medicines Supply but has Wider Ambitions for Improved Accessibility of Other Medicinal products by Creating a Framework for Collaborative Procurement

by Els Janssens, Olha Sviatenka and Marie-Hélène Van Hoof

New White House Executive Order to Establish “Most-Favored-Nation” Drug Pricing

Medical Devices March 13, 2025

The Impact of Tariffs on the Life Sciences Industry

Import tariffs have become the priority trade issue since President Donald Trump took office on January 20, 2025, with a wide variety of measures…

Health Data Privacy & Security March 5, 2025

European Health Data Space Regulation Published – What’s Next?

On 5th March 2025, the European Health Data Space (EHDS) Regulation was officially published in the Official Journal of the European Union. The EHDS…

Healthcare Services January 20, 2025

Hungary to introduce important changes to named patient reimbursement

In Hungary, certain decisions on named patient reimbursement of medicinal products and medical aids will be made by a public benefit foundation in addition…

EU Pharmaceutical Package

In EU Pharmaceutical Package

A New Dawn for the EU Pharma Regulatory Regime? The Commission’s Proposal to Revise the EU Pharmaceutical Legislation is Finally Published

April 26, 2023 by Els Janssens, Magda Tovar and Julia Gillert 5 Mins Read

Today the European Commission has finally published its Proposal to revise the EU Pharmaceutical legislation, the most momentous…

In EU Pharmaceutical Package

EU Pharma Package: How Significant are the Proposals for Orphan Medicines?

May 16, 2023 by Els Janssens, Magda Tovar and Julia Gillert 6 Mins Read

On 26 April 2023 the European Commission published its Proposals to Reform the EU pharmaceutical legislation.[1] We continue…

In EU Pharmaceutical Package

Hungarian Pricing and Reimbursement Reforms Aiming to Remove Hurdles to Late Market Access of Innovative Pharmaceuticals

May 26, 2023 by Dr. Helga Bíró M.Jur. and Máté Laczkó 3 Mins Read

In brief Reimbursing medicinal products is critical to ensure that treatments are widely available to patients. This is…

In EU Pharmaceutical Package

The EU Pharmaceutical Package From a National Perspective: Member States’ First Reactions

May 30, 2023 by Els Janssens, Julie Yeni, Dr. Martin Altschwager LL.M., Dr. Frank Pflueger and Magda Tovar 6 Mins Read

The Proposal to revise the EU Pharmaceutical legislation has generated unprecedented levels of attention, not only across the…

In EU Pharmaceutical Package

The Future is Green: Eco Measures are Embedded into the EU Reform Proposals

June 13, 2023 by Julia Gillert, Els Janssens and Magda Tovar 2 Mins Read

As previously covered in this blog, on 26 April 2023 the European Commission published a set of proposals…

In EU Pharmaceutical Package

Supply Chain Protection: What do the EU Reform Proposals Look Like and do They go Far Enough?

June 13, 2023 by Julia Gillert, Els Janssens and Magda Tovar 3 Mins Read

As already well noted on this blog, on 26 April 2023 the European Commission published a set of…